OINDP experts will gather once again in Palm Desert, California from April 26-30 for the 2020 edition of the Respiratory Drug Delivery (RDD) conference. As with past RDD meetings, attendees will find a scientific program and poster exhibition featuring the latest in aerosol drug delivery science, a technology exhibition with companies offering products and services, and plenty of networking opportunities.
Noting last year’s record attendance at RDD Europe 2019, Richard Dalby of RDD Online says that RDD 2020 seems to be benefitting from a sustained level of interest. One measure of excitement surrounding the meeting, he notes, is that the organizers have received more than 100 poster abstracts covering recent research on a wide range of topics.
Dalby says that he finds the first day’s focus on potential new therapies and new targets particularly intriguing: “It seems like we’ve had a couple of decades of recombining old drugs in different ways, putting together new combinations and designing new platforms, and the possibility of new drugs administered by inhalation is always exciting.”
On the first day of the meeting, Oliver Eickelberg of the University of Colorado will present the plenary lecture titled, “The Etiology of Fibrotic Interstitial Lung Diseases: Diagnostic Challenges and Treatment Strategies.” That talk will be followed by a session on inhaled therapies for pulmonary infections, especially mycobacterial lung infections.
Other topics that Dalby thinks will generate a lot of buzz at the meeting include the development of Koura’s Zephex 152a as a potential new MDI propellant and the continuing efforts to create generic versions of Advair and other inhaled products.
The complete list of program topics for RDD 2020 includes:
- Advances in Difficult-to-Treat Pulmonary Infections
- Airway Remodeling or Renovation?
- New DPI Theory and Practice
- Clinically Relevant Testing in NDA and Lifecycle Submissions
- Evaluating Nasal Drugs: Improving Topical and Nose-to-Brain Delivery
- Reducing Our Carbon Footprint
- The Impact of New Technology & Regulation on Inhaler Design, Development & Product Lifecycle
The final session, titled, “The Impact of New Technology & Regulation on Inhaler Design, Development & Product Lifecycle,” is a joint RDD/IPAC-RS session, providing a lead-in to an IPAC-RS Symposium on “The Global Regulatory Landscape and Advances in Digital Technology” that will follow RDD.
